Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.09.050 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.09.050 34571149!8461267!34571149     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2022 ; 122 (ä): 155-161 Nephropedia Template TP {{tp|p=34571149|t=2022. Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment |pdf=|usr=}}{{34571149}} gab.com Text Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34571149 #FOAvip INTRODUCTION: We assessed the potential relationship between COVID-19 and laboratory-confirmed cutaneous leishmaniasis (CL)-registered cases with a history of scarring, compared with volunteer participants without history of CL. METHODS: This case-control retrospective study was conducted in southeastern Iran with a high anthroponotic cutaneous leishmaniasis (ACL) burden. RESULTS: Overall, n=1010 CL cases (n=479 male, n=531 female) were evaluated for infection with SARS-CoV-2. In the CL case group, 2 men and 1 woman (0.3% in total) had a mild form of COVID-19 disease; none were hospitalized or died. In contrast, of n=2020 participants without history of CL, n=57 (2.9%) contracted laboratory-confirmed COVID-19, including mild (66.7%), hospitalized (26.3%), critical (3.5%) and fatal (3.5%). There was a strong negative association between CL infection and COVID-19. The burden of COVID-19 in CL-cured participants significantly reduced the morbidity (odds ratio: 0.12; CI: 0.03-0.30; P <0.001) and mortality (percentile: -4.10, -0.02). CONCLUSION: Participants with a history of CL scar had significantly reduced incidence of COVID-19 morbidity and mortality. The cross-protection mediated by CL may retard COVID-19 in endemic countries. However, further longitudinal studies are needed to explore the potential profile and duration of this protection offered by CL against COVID-19. Twit Text FOAVip Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34571149 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34571149 #FOAvip English Wikipedia <ref>{{Cite pmid|34571149}}</ref> Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment #MMPMID34571149 Bamorovat M; Sharifi I; Aflatoonian MR; Karamoozian A; Tahmouresi A; Jafarzadeh A; Heshmatkhah A; Sharifi F; Salarkia E; Khaleghi T; Khosravi A; Nooshadokht M; Zarandi MB; Barghi M Int J Infect Dis 2022[Sep]; 122 (ä): 155-161 PMID34571149show ga INTRODUCTION: We assessed the potential relationship between COVID-19 and laboratory-confirmed cutaneous leishmaniasis (CL)-registered cases with a history of scarring, compared with volunteer participants without history of CL. METHODS: This case-control retrospective study was conducted in southeastern Iran with a high anthroponotic cutaneous leishmaniasis (ACL) burden. RESULTS: Overall, n=1010 CL cases (n=479 male, n=531 female) were evaluated for infection with SARS-CoV-2. In the CL case group, 2 men and 1 woman (0.3% in total) had a mild form of COVID-19 disease; none were hospitalized or died. In contrast, of n=2020 participants without history of CL, n=57 (2.9%) contracted laboratory-confirmed COVID-19, including mild (66.7%), hospitalized (26.3%), critical (3.5%) and fatal (3.5%). There was a strong negative association between CL infection and COVID-19. The burden of COVID-19 in CL-cured participants significantly reduced the morbidity (odds ratio: 0.12; CI: 0.03-0.30; P <0.001) and mortality (percentile: -4.10, -0.02). CONCLUSION: Participants with a history of CL scar had significantly reduced incidence of COVID-19 morbidity and mortality. The cross-protection mediated by CL may retard COVID-19 in endemic countries. However, further longitudinal studies are needed to explore the potential profile and duration of this protection offered by CL against COVID-19. |*COVID-19[MESH] |*Leishmaniasis, Cutaneous/epidemiology/prevention & control[MESH] |Case-Control Studies[MESH] |Female[MESH] |Humans[MESH] |Iran/epidemiology[MESH] |Male[MESH] |Retrospective Studies[MESH]Prophylactic effect of cutaneous leishmaniasis against COVID-19: a cas(epmc).pdf DeepDyve Pubget Overpricing